Kimberly M. Baker
Novo Nordisk and Sanofi announced last week that they will lower prices on some of their insulin products by up to 78% effective January 2024. That follows Eli Lilly’s recent announcement that it will lower some of its insulin prices by 70% later this year.
My son – who was diagnosed with Type 1 diabetes, an autoimmune disease that destroys the body’s ability to make insulin – obtains his insulin from Novo Nordisk, and so this news brings significant financial relief for my family.
Source link
